News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Prescribing Patterns: How to Get Ahead of the Trends

April 9, 2020
By Janardhan Vellore and Daniel Wetherill
Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-04-01-2020
Volume 40
Issue 4

The key to success in a hypercompetitive marketplace is to create targeting plans that get ahead of tomorrow’s prescriptions.

In today’s hypercompetitive biopharmaceutical marketplace, prescribing behaviors are shifting rapidly, in line with fast-paced, market-moving events. A high-volume prescriber of a drug can quickly become a low-volume prescriber and vice versa. Unfortunately, too many biopharma segmentation and targeting plans are built for the more static industry of the past, basing plans on historical prescription volume. This leads to three big problems for brand marketers:

  • Anemic brand launches.

  • Inability to counter competitors’ launches.

  • Flatlining of brand growth.

The key to success is to create targeting plans that get ahead of tomorrow’s prescriptions. But a backward-looking volumetric approach to targeting can inadvertently lead a brand team to overcommit resources to reaching historically high-volume prescribers, often at the expense of middle-tier or low-tier ones who may be on the cusp of becoming top prescribers in the near future. These emerging growers can represent a significant opportunity for a brand. The traditional approach similarly can’t help a team recognize when a prescriber is on the verge of switching a significant number of prescriptions for the company’s brand to a competing brand (emerging switchers). And it certainly can’t help a brand team identify those who don’t yet write the company’s drug but are ripe to be converted (emerging adopters).

If a brand team were able to identify these emerging growers, switchers, and adopters, it could use a custom mix of sales and marketing tactics to reach them with messages that resonate and convert these emerging brand opportunities. But this proactive effort is impossible when a brand team relies on historical prescription data trends to dictate its future targeting strategy. By overhauling the old framework and deploying sophisticated big data management, advanced analytics, and machine learning (ML) techniques, teams can uncover the hidden trends within large volumes of prescriber- and anonymized patient-level data, identify strategically important prescribers, and proactively increase the breadth and depth of prescriptions.

Make targeting smarter

ML can help a brand team discover underlying patterns within big data sets that aren’t easy to discern using traditional analytical approaches or simple rules-based algorithms. Armed with these insights, the team can identify the distinguishing characteristics of emerging growers, switchers, and adopters. From there, it can score and rank target HCPs or accounts within each category based on the likelihood of growth, switching, and adoption in the near-term, and create a dynamic target list that drives the call plan. After that, the  team can craft and deploy tailored sales and marketing tactics and messages to engage with these targets and convert them.

One of the biggest impediments to successfully executing ML projects is poorly organized data. The brand team must create an organized repository of prescriber- and anonymized patient-level data and incorporate data on its current sales and marketing outreach. It should fold in prescriber attributes, prescription data for competing drugs, as well as relevant information about patients’ treatment journeys, where applicable.

Another step in implementing dynamic targeting is to measure its effectiveness. A small portion of the sales force can continue to use the traditional, volumetric-based targeting plan, while the majority of the sales team uses the new ML-based plan. The brand team can then compare sales results to measure and validate the effectiveness of its new approach.

Embed into call plans

Industry trends give biopharma companies little choice but to embrace ML-informed dynamic targeting. Some companies have already fully integrated ML-based insights into their call plans. Others operate in an intermediate stage on this path toward dynamic targeting. For example, a firm may still use a traditional, volume-based call plan, but also leverage simple rules-based algorithms to analyze recent prescribing trends and send time-sensitive alerts to reps regarding targets in their territories. But these algorithms and alerts can miss the underlying prescribing patterns and emerging trends that ML techniques would help the company identify. It can also be onerous for reps to change their call plans on short notice in response to these ad hoc alerts.

Companies in this intermediate stage should seek to push beyond it. A wholehearted embrace of ML-driven dynamic targeting as the basis of call plans will help them navigate a rapidly changing prescriber landscape with necessary agility.

Janardhan Vellore is a Vice President and Daniel Wetherill is a Partner, both at Beghou Consulting

 

Download Issue PDF
Articles in this issue

HBA's Woman of the Year 2020: A Motivated Mission
HBA's Woman of the Year 2020: A Motivated Mission
Doubling Down on D&I
Doubling Down on D&I
Lisa Henderson thumbnail.jpg
COVID-19 Ripple Effects for Pharma
Dan Wetherill.jpg
Prescribing Patterns: How to Get Ahead of the Trends
Globla Report PQ.png
There’s No Easing the Price-vs.-Value Debate
Gene fig 4.png
Payer Perspectives on Gene Therapy Reimbursement
Wash Report side.png
Covid-19 Pandemic Thrusts Biopharma R&D to Forefront
Transforming the CIO Role to Embrace Digital Health
Pharmaceutical Executive, April 2020 Issue (PDF)
Country Report: The Czech Republic
Recent Videos
Related Content

© JHVEPhoto - ©  JHVEPhoto - stock.adobe.com

FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research

Andy Studna
May 21st 2025
Article

In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


FDA Advisory Committee Backs J&J’s Darzalex Faspro for High-Risk Smoldering Multiple Myeloma

FDA Advisory Committee Backs J&J’s Darzalex Faspro for High-Risk Smoldering Multiple Myeloma

Don Tracy, Associate Editor
May 21st 2025
Article

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex Faspro in patients with high-risk smoldering multiple myeloma.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Christopher Wooden

The Promise of Agentic AI to Cut Through HCP Marketing Overwhelm

Christopher Wooden
May 21st 2025
Article

Prioritizing deeper customer insights helps life sciences marketers understand how to engage their HCP audiences effectively with the right message.


Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Related Content

© JHVEPhoto - ©  JHVEPhoto - stock.adobe.com

FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research

Andy Studna
May 21st 2025
Article

In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


FDA Advisory Committee Backs J&J’s Darzalex Faspro for High-Risk Smoldering Multiple Myeloma

FDA Advisory Committee Backs J&J’s Darzalex Faspro for High-Risk Smoldering Multiple Myeloma

Don Tracy, Associate Editor
May 21st 2025
Article

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex Faspro in patients with high-risk smoldering multiple myeloma.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Christopher Wooden

The Promise of Agentic AI to Cut Through HCP Marketing Overwhelm

Christopher Wooden
May 21st 2025
Article

Prioritizing deeper customer insights helps life sciences marketers understand how to engage their HCP audiences effectively with the right message.


Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.